161 Fort Washington AveNew York, NY 10032
Overview of Dr. Cherng
Dr. Hua-Jay Cherng is a New York-based oncologist with a subspecialty in hematologic oncology. He has been educated and trained at prestigious institutions, starting at Case Western Reserve University School of Medicine, followed by his internship and residency at University of Pennsylvania Health System, and his fellowship at University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Professional experience ranges from Resident Physician at the Hospital of the University of Pennsylvania to Clinical Fellow at University of Texas M.D. Anderson Cancer Center. His expertise lies in internal medicine and medical oncology. He has an impressive list of publications in esteemed journals, discussing various aspects of lymphoma, DLBCL treatment, and CAR T-cell therapy.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
University of Pennsylvania Health SystemInternship, Internal Medicine, 2016 - 2019
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2016 - 2019
Case Western Reserve University School of MedicineClass of 2016
Certifications & Licensure
NY State Medical License 2022 - 2027
TX State Medical License 2019 - 2024
PA State Medical License 2018 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.Evelyn H Orlando, Patrick Gould, Brian Cuzzo, Maegan Ford, Yuxuan Chen
Blood Neoplasia. 2025-11-01 - Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando
Leukemia & Lymphoma. 2025-08-14 - 1 citationsRemission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.Mark Roschewski, David M Kurtz, Jason R Westin, Ryan C Lynch, Ajay K Gopal
Journal of Clinical Oncology. 2025-08-13
Press Mentions
Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma PatientsDecember 5th, 2024
Grant Support
- Circulating tumor DNA guided de-escalation of frontline diffuse large B-cell lymphoma therapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2024–2026
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
